Dr. Dhankhar currently serves as the HEOR lead at CHEORS, where his primary responsibility is the adaptation of models to support reimbursement efforts. Prior to joining CHEORS, he worked in the pharmaceutical industry and Center for Disease Control as a health economist for nearly 10 years. Dr. Dhankhar has worked extensively in multiple disease areas including vaccines, oncology, diabetes, cardiovascular diseases, infectious diseases, and ultra-rare diseases. He is an expert in economic modeling, country submissions for HTA review, and developing strategy to generate value evidence for products. He has launched products both globally and in US and has extensive experience in working with country affiliates. He has helped countries understand various economic models, created input sheets to be shared with countries, and assisted countries with collecting data for model inputs. He has also generated reports and slide decks based on the model analysis to be shared with the countries.
Dr. Bagga is Senior Director, HEOR, at CHEORS. Prior to joining CHEORS, she worked in the pharma industry, consulting, and Centers for Disease Control and Prevention (CDC) for more than 12 years. She has worked extensively in multiple disease areas including vaccines, pain management, respiratory, and biologics. Shalini has helped to conduct multi-country studies worldwide and collect data. She has helped to launched products both globally and in the US and has extensive experience in working with country affiliates. She currently leads the systematic literature review, meta-analysis, and dossier creation at CHEORS.
Dr. Cook currently serves as Vice President for Economic Modeling at CHEORS. In this capacity, he is responsible for overseeing the development of all new health economic models at CHEORS, and personally directs many of them. Prior to joining CHEORS, John served as Executive Director and headed (for 15 years) the Health Economic Statistics Department in CORE at Merck & Co., Inc. Dr Cook and his team were responsible for the development and adaptation of health economic models to project the long-term impact of treatment on health outcomes and cost. John also gained valuable experience analyzing clinical trial data for economic purposes. With nearly 30 combined years of experience, he is an expert in developing and guiding teams to develop cost-effectiveness and budget impact models and in capitalizing on clinical trial data for health economic purposes. Dr. Cook has published over 40 articles, book chapters and reviews in health economics and statistics and has taught short-courses on conducting economic evaluations at several venues, including the Joint Statistical Meetings, International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conferences, International Health Economics Association Conference, and at the Stockholm School of Economics. He also served on two ISPOR Good Research Practices Task Forces – for Randomized Clinical Trial-Cost Effectiveness Analysis (RCT-CEA) and for Economic Data Transferability.
Dr. Lakshminarayanan currently serves as Vice-President, Clinical and Database Studies at CHEORS. He has over 30 years of experience working in the pharmaceutical industry. Dr. Lakshminarayanan has held several positions both in the management as well as in research. He has worked on several therapeutic areas including neuroscience, bone, respiratory, immunology, and endocrinology. More recently, he has spent over five years working on designing and reporting Phase-I and POC trials in oncology. During this time, he has developed and implemented methodologies for Early Sing of Efficacy and Signs of Clinical Activity. Dr. Lakshminarayanan has strong conceptual and working knowledge in the application of Bayesian methods and adaptive design methodologies in clinical trial development. He has published over 50 articles, technical reports and book chapters. He is active in personal research and currently a core member of the Development Committee of the American Statistical Association (ASA). He is also a Fellow of the ASA. He has served as a referee for several journals. Mani is also a part-time lecturer at the Department of Statistics and Biostatistics/Rutgers University. He is currently editing a book (as a co-author) on the Bayesian Applications in Pharmaceutical Development which is expected to be published in 2018.
Dr. Dhanda currently serves as the Real-World Evidence (RWE) lead at CHEORS, where his primary responsibility is the generation of evidence from observational studies that utilize either databases, patient registries, or pragmatic trials. Prior to joining CHEORS, he worked in the pharmaceutical, biotech, and medical device sectors of the industry, and with contract research organizations. Dr. Dhanda also holds an adjunct associate professorship with the University of Texas Health Science Center in San Antonio. Having worked in different segments of the health care industry for over 25 years, he has developed a diverse background that underlies his analytical capabilities to understand, execute and produce quality work on high priority projects. Dr. Dhanda has worked in multiple therapeutic areas including, oncology, CNS, cardiovascular diseases, dermatology, pain, infectious diseases, and rare diseases. He is an expert in the use of statistical methods to analyze data. He is on the editorial board of an applied statistical journal and has been a peer reviewer for several academic journals. He is also actively engaged with ISPOR, ISPE, and ISOQOL. He has published his research in many peer reviewed journals, and presented his research findings at various medical conferences.
Michael Marentette is Director, HEOR & Reimbursement, and the Canada Country Lead for CHEORS. Michael has over 20 years of experience in Market Access and HEOR in the pharmaceutical industry, including 15 years at Merck Canada and Janssen and over 5 years of consulting experience. Michael has demonstrated leadership and high performance in shaping and delivering value propositions to fully leverage the reimbursement potential of Government and private sector formulary listings across Canada in multiple therapeutic areas for a number of pharmaceutical and biologic products, including some of the industry’s biggest brands. Michael has led the planning and development of multiple Health Economics models, Budget Impact Analyses and Outcomes Research studies, several of which resulted in peer-reviewed publications. Michael has held several senior management roles, including Director of Reimbursement with Merck Canada, and has served on global Market Access planning committees.